Randomized, Three Period Cross Over, Double Blind, Double Dummy Study in Type 2 Diabetic Patients to Assess the Endothelial Effects of Linagliptin, Glimepiride and Placebo Therapy for 28 Days ('ENDOTHELINA')
Phase of Trial: Phase I
Latest Information Update: 18 Sep 2015
At a glance
- Drugs Linagliptin (Primary) ; Glimepiride
- Indications Type 2 diabetes mellitus
- Focus Pharmacodynamics
- Acronyms ENDOTHELINA
- Sponsors Boehringer Ingelheim; Boehringer Ingelheim Pharmaceuticals
- 22 Jan 2014 According to ClinicalTrials.gov record study status changed from active, no longer recruiting to completed.
- 18 Sep 2013 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
- 08 Aug 2013 Planned end date changed from 1 Nov 2013 to 1 Jan 2014 as reported by ClinicalTrials.gov.